Member Info for Croasdalelfc

I’ve just read that paper. The Tumours were already known and TexRad was used not to detect new tumours but to characterise High grade tumours from low grade tumours . The 2mm reference wasn’t to the size of the tumour but the type of texture analysis . Fine or coarse. You guys are obviously not technical, or scientific or have any skin in the game of radiography, radiotherapy, oncol

Thanks Horsford for welcoming other views. I would love to buy this share if I thought it was ground breaking software with the ability to detect lesions that are otherwise not detectable. That would definitely lead to changes in patient management and potentially save money and possibly lives. Unfortunately any techniques which upstage cancer ie finding distant metastasis is a negative for the patient but can stop unnecessary surgery/chemotherapy/radiotherapy which could save money. Please show me one case study where TexRad finds a lesion smalller than 5mm which was not seen on conventional Imaging . CT generally picks up lesions 5mm plus these generally lesions that have grown ie CT is picking up anatomical changes. PETCT can pick up metabolic changes before lesions have grown very much from 2.5mm plus but is only used for 4-5 cancers, bowel, lung, lymphoma , prostate, oesophageal and melanoma. For instance it’s not very good for breast cancer. If TexRad can pick up lesions from 2mm that can be characterised as tumours from the texture analysis that would be a USP. If TrxRad could characterise larger lesions as definitely cancer without the need for a biopsy that would be a USP. Please show me a case study where TexRad has a USP. NB the software in the video that I linked to earlier can pick up lesions from 3mm and also characterise them as solid or partially solid (ie calcified). That software has been around for 10 years

At £100m Mcap share price should open at 500p Does anyone think they will do a placing to raise cash to buy more assets? They are supposed to be targeting 10-15 kbopd? Will cash from the acquisitions be used instead? They will have FCF of $2 million a week. Can anyone work out how much cash they have left?

as these have been around for years and i cant get any information from TexRad website other than a video from 2010 and posters from 2012. computer assisted detection and characterisation of lesions has been around for 10 years https://www.youtube.com/watch?v=Ovvu3cVlQOo https://www.youtube.com/watch?v=QxiOgQDM5qc https://www.healthcare.siemens.com/computed-tomography/options-upgrades/clinical-applications/syngo-lungcare-ct-and-syngo-lung-cad

Also there is a new presentation on website. Cash left at end Sept is $1.2m - enough for 6 weeks - though they have a bank loan agreed for $1.5m Cash burn approx $670k a month. All in all they have approx 4 months cash left

Reiterates : highly confident of meeting Q4 sales target. Fixed opex and any increase in basket price and or increase in tonnage processed will go straight to the bottom line. Processing plant has capacity to process double the tonnage